These features are all associated with more aggressive tumour growth and worse prognosis [[19], [20], [21], [22]], and therefore chemotherapy is likely more effective in BRCA1 mutation carriers (and by extension in the prevention of secondary breast tumours, having similar characteristics, at least in our dataset). Here, BRCA1 is linked to neoplasm.